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Background: Lung cancer constitutes one of the malignancies with the greatest incidence and mortality rates with
1.6 million new cases and 1.4 million deaths each year. Prognosis remains poor due to deleterious development of
multidrug resistance resulting in less than 15% lung cancer patients reaching five years survival. We have previously
shown that Phyllanthus induced apoptosis in conjunction with its antimetastastic action. In the current study, we
aimed to determine the signaling pathways utilized by Phyllanthus to exert its antimetastatic activities.
Methods: Cancer 10-pathway reporter array was performed to screen the pathways affected by Phyllanthus in lung
carcinoma cell line (A549) to exert its antimetastatic effects. Results from this array were then confirmed with
western blotting, cell cycle analysis, zymography technique, and cell based ELISA assay for human total iNOS.
Two-dimensional gel electrophoresis was subsequently carried out to study the differential protein expressions in
A549 after treatment with Phyllanthus.
Results: Phyllanthus was observed to cause antimetastatic activities by inhibiting ERK1/2 pathway via suppression of
Raf protein. Inhibition of this pathway resulted in the suppression of MMP2, MMP7, and MMP9 expression to stop
A549 metastasis. Phyllanthus also inhibits hypoxia pathway via inhibition of HIF-1α that led to reduced VEGF and
iNOS expressions. Proteomic analysis revealed a number of proteins downregulated by Phyllanthus that were
involved in metastatic processes, including invasion and mobility proteins (cytoskeletal proteins), transcriptional
proteins (proliferating cell nuclear antigen; zinc finger protein), antiapoptotic protein (Bcl2) and various glycolytic
enzymes. Among the four Phyllanthus species tested, P. urinaria showed the greatest antimetastatic activity.
Conclusions: Phyllanthus inhibits A549 metastasis by suppressing ERK1/2 and hypoxia pathways that led to
suppression of various critical proteins for A549 invasion and migration.
Keywords: Phyllanthus, Metastasis, Apoptosis, ERK1/2, HIF-1αBackground
Lung cancer constitutes one of the malignancies with
the greatest incidence and mortality rates with 1.6 million
new cases and 1.4 million deaths each year [1,2]. Although
initial use of platin-based cytotoxic chemotherapy improved
the overall survival rate and life quality of the patients, the
outcome remains poor due to deleterious development of
drug resistance resulting in less than 15% lung cancer
patients surviving for at least five years [2,3]. Approximately* Correspondence: shamalamy@yahoo.com
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reproduction in any medium, provided the or80 - 85% of the lung cancer patients are diagnosed with an
advanced stage of non-small cell lung cancer (NSCLC) that
has limited therapeutic options due to metastasis [1,4,5]
and among the three types of NSCLC, patients identified
with squamous carcinoma which involves lymph node
metastasis accounts for 60% [5,6]. In the advance stage of
NSCLC, surgery is not possible to remove all apparent
lesions hence leading to the high rate of cancer recurrence
[7]. Therefore, lethality of lung cancer is often attributed to
late diagnosis, metastasis, and the occurrence of drug
resistance [8]. Thus, the development of an efficient
cancer diagnostic method is crucial since an early detection
of cancer while it is still localized and curable is one of the. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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burden [9]. This requires an understanding of the patho-
physiology of the disease [10,11] which can be made
possible via proteomic studies. Cancer proteomics
allow the screening of early diagnostic markers or potential
drug targets [6] by comparing the proteomes of the
diseased and diseased-treated samples that allows
identification of aberrantly expressed proteins [5,10].
These proteins could be biomarker candidates to expedite
non-invasive diagnosis of early-stage malignant tumor, as
well as to aid the monitoring of tumor progression and
therapy effectiveness [12]. Similar to other malignant
pathologies, tumor markers for NSCLC remained inad-
equate. Serum biomarkers employed in the current
clinical setting such as ENO (enolase alpha), CEA
(carcinoembryonic antigen), SCC (squamous cell carcinoma),
CA-125 (cancer antigen 125) or TPA (tissue polypeptide
antigen) are not satisfactory due to their low sensitivity and
specificity [13,14]. In the quest for novel diagnostic or
prognostic biomarkers, the proteomic technique is
ideal since it permits qualitative and quantitative analysis
of numerous proteins simultaneously [9,13]. Moreover,
the search for biomarkers at the protein level is more
dependable than at the transcriptional level as protein
expression may not necessarily associate with mRNA
expression [14].
Natural-product based drugs are gaining their popularity
as preventive medicines or for health management, and
hence this has spurred an intensive search for bioactive
plant-derived anticancer compounds [15]. The genus
Phyllanthus is one of the most widely distributed plants
throughout the Amazon rainforests as well as other tropical
and subtropical regions. Abundant studies on Phyllanthus
spp. started in the late 1980′s when the clinical efficacy of
Phyllanthus niruri against viral Hepatitis B was observed
[16]. Various therapeutic actions of this genus have been
reported, including being antihepatotoxic, antilithic, antihy-
pertensive, anticarcinogenic, and most recently anti-HIV as
well [16-19]. We have demonstrated antimetastatic and
antiproliferative activities of Phyllanthus against several
metastatic cell lines such as lung carcinoma (A549), breast
(MCF-7) carcinomas [17], melanoma (MeWo), as well as
prostate (PC-3) carcinoma [20].
Nevertheless, the exact mechanisms for the antimetastatic
activities of Phyllanthus are still uncertain. MAP kinase
(MAPK) is one of the signaling pathways known to mediate
metastasis via transmission of extracellular stimuli into the
nucleus that activate the serine/threonine kinases which
belong to the MAPK superfamily [21]. MAPK serine/
threonine superfamily is made up of three well-described
subgroups, including ERK1/2 or p44/42 MAPK, JNK/
SAPK, and p38 MAPK. These diverse pathways with dis-
tinct downstream targets are activated by various stimuli
to regulate cell proliferation, apoptosis, and metastasis[21,22]. Regulation of metastasis by MAPK is mainly via con-
trolling the cells’ expression of matrix metalloproteinases
(MMPs) enzymes by decreasing the nuclear levels of NFκB,
c-Fos, or c-Jun [21,22]. The MMPs are a family of at
least 20 members of highly homologous, zinc- and
calcium-dependent endopeptidases which can degrade
virtually all extracellular matrix (ECM) components
[23]. Among these MMPs, MMP2 and MMP9 are
abundantly expressed, secreted, and activated in various
malignant tumors [22,24]. Recent studies also shown that
MMP7 plays an essential role in ectodomain shedding of
cell-surface molecules such as EGFR, HB-EGF, Fas ligand,
and E-cadherin in addition to its ability to degrade ECM
components. Therefore, these enzymes are the most vital
ones implicated in cancer invasion and metastasis [24,25].
Hypoxia pathway is another chief regulator of metastatic
process. Hypoxia-inducible factor-1 (HIF-1) is the deter-
mining factor for oxygen-dependent gene regulation and is
a dimer of HIF-1α and HIF-1β. Its regulation is mainly
governed by the transactivation and stabilization of HIF-1α
protein resided in the cytoplasm [26]. Under normoxia con-
dition, HIF-1α instantaneously interacts with von Hipple–
Lindau (pVHL) ubiquitin E3 ligase complex and is targeted
for proteasomal degradation due to hydroxylation of two
specific proline residues within the oxygen-dependent deg-
radation domain by prolyl hydroxylases [7,26]. Contrarily,
HIF-1α will be stabilized with increased expression during
hypoxic condition, allowing it to translocate into the nu-
cleus and dimerize with HIF-1β. HIF-1 will subsequently
bind to the hypoxia response elements to regulate transcrip-
tion of over 100 target genes which favors tumor growth
and metastasis, including vascular endothelial growth factor
(VEGF) as well as genes that regulate cellular processes
such as energy metabolism, cell proliferation, vascular
development and remodelling, as well as vasotone [2,7,26].
In our previous study, Phyllanthus extracts were shown
to inhibit A549 (lung carcinoma) cells growth with IC50
values ranging from 60–130 μg/ml and 200–470 μg/ml
for methanolic and aqueous extracts respectively [17]. We
also demonstrated that they effectively reduced invasion,
migration, and adhesion activities of A549 cells in a dose-
dependent manner and was capable of inducing apoptosis
along with its antimetastastic action [17]. Therefore, the
main objective of this study was to determine the protein
expression profile of Phyllanthus-treated A549 cells and
how the signaling pathways were utilized by Phyllanthus
in order to exert its antiproliferative and antimetastatic
activities on this cell line.
Methods
Plant extracts and standard drugs
The crude extracts (aqueous and methanolic) of each
Phyllanthus spp., namely P. niruri, P. urinaria, P. watsonii
and P. amarus, were obtained from the Malaysian
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(MARDI), Malaysia. The aqueous extracts were prepared
by dissolving 10 mg in 1ml of sterile PBS (Final concentra-
tion 10 mg/ml), whereas, the methanolic extracts were
prepared by dissolving 40 mg in 1ml of DMSO (Final con-
centration 40 mg/ml). The tubes containing the extracts
were wrapped with aluminium foil and stored at -20°C
until use. A single batch of extracts was used for all the ex-
periments. The IC50 concentrations that were used as one
of the treatment conditions in most of the experimental
assays (Table 1) as well as the polyphenol contents of these
extracts have been determined and published in the previ-
ous study [17]. Cisplatin and Doxorubicin (MERCK –
1 mg/ml) as standard anticancer drugs for lung and breast
carcinomas respectively were included as the controls.
Cell culture
Human lung carcinoma (A549) cell line was purchased
from American Type Culture Collection (ATCC, USA)
and was grown in RPMI-1640 (Roswell Park Memorial
Institute). To ensure growth and viability of the cells,
the mediums were supplemented with 10% FBS (Gibco)
and incubated in a humidified atmosphere with 5% CO2
at 37°C.
Transient transfection and cancer 10-pathway
reporter array
Cancer is a group of diseases strongly correlated with de-
fects in signal transduction proteins. Various key signaling
pathways have been implicated in human tumorigenesis.
Analysis of these signaling pathways was performed
using Cignal Finder Cancer 10-pathway Reporter
Array kit (SABiosciences, QIAGEN, USA). Transient
transfection was performed using TransIT-LT1 (Mirus
Bio, USA). Both plasmid DNAs for the respective signal-
ing pathways provided in the kit as well as TransIT-LT1
were diluted using Opti-MEM I reduced serum mediumTable 1 Cytotoxic effect [IC50 (μg/ml)] of Phyllanthus
extracts against A549 and MCF-7





P. niruri (P.n) Aqueous 466.7 ± 41.63 179.7 ± 0.58
Methanolic 128.3 ± 17.56 62.3 ± 9.07
P. urinaria (P.u) Aqueous 215.0 ± 21.79 139.3 ± 1.16
Methanolic 69.0 ± 11.53 48.7 ± 10.02
P. watsonii (P.w) Aqueous 198.3 ± 10.41 104.0 ± 10.39
Methanolic 61.3 ± 16.17 49.0 ± 8.19
P. amarus (P.a) Aqueous 240.0 ± 26.46 156.7 ± 5.77
Methanolic 126.7 ± 7.64 56.3 ± 6.66(Invitrogen, USA). After that, plasmid DNAs and the
TransIT-LT1 was mixed to allow TransIT-LT1/DNA
complex formation. Subsequently, 90 μl (approxi-
mately 10000 cells) of the cell suspension were mixed
with 10 μl of the complex and added into the desig-
nated wells of a 96-well cell culture white microplate
(Nunc, Thermo Fisher Scientific, USA). The culture
plate was rocked for 5 minutes on a rocker before it was
incubated in a 5% CO2 incubator at 37ºC overnight. After
the transfection of cells with various plasmid DNAs for the
respective signaling pathways, the cells were incubated with
different Phyllanthus extracts for another 24 hours. Dual-
Glo Luciferase reagent was then added into each well and
incubated at room temperature for 10 minutes before
reading the firefly luminescence generated using the
GloMax Multi Detection System (Promega, USA). This was
followed by the addition of Dual-Glo Stop & Glo reagent to
all wells. Similarly, another renilla luminescence reading
was obtained after the plate was incubated for another
10 minutes. The firefly constructs monitor changes in the
activity of a key transcription factor which is a downstream
target of a particular signaling pathway. Meanwhile, renilla
construct acts as an internal control for transfection effi-
ciencies normalization as well as to monitor cell viability.
Luminescence for each wells were determined by calculat-
ing the ratio of its firefly to renilla luminescence.
Cell cycle analysis
DNA content analysis is performed by Propidium iodide
(PI) staining which binds to the distinct amount of DNA
content in the cells at different phases of the cell cycle.
Briefly, cells were seeded at 105 cells/well, treated with
extracts at their IC50 values, and incubated at various
time periods from 0 to 72 hours. At the end of each incuba-
tion period, cells treated with or without Phyllanthus
extracts were harvested and fixed with ice-cold 70% ethanol
for at least 1 hour at -20ºC. Cells were then pelleted, washed
once with PBS, resuspended in the PI solution [10μg/ml PI
(Sigma) and 1mg/ml RNase A in PBS], and incubated
in a 37°C water bath for 30 minutes. Data acquisition
was performed using a Becton Dickinson FACSCalibur
flow cytometer and CellQuest software and subsequently
analysed using WinMDI 2.9 software. The distribution of
cell percentages in each cell cycle phase is determined by
setting gates based on their amount of DNA content.
Preparation of cytoplasmic protein lysate
Protein lysates were prepared for western blotting and
proteomic analysis for both Phyllanthus-treated and
untreated samples. Cells treated with Phyllanthus
extracts were detached from the culture plates using
0.5% trypsin-EDTA and washed twice with phosphate
buffered saline (PBS), centrifuging at 1500 rpm for
5 minutes. Two hundred microliters of lysis buffer
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40 mM DTT) was added to the cell pellet and incubated
on ice for 30 minutes before collecting the supernatant
into a new 1.5 ml tube followed by addition of 4× sample
volume of iced-cold acetone. After that, the sample was in-
cubated at -20°C overnight and centrifuged at 14000 rpm
for 15 minutes at 4°C. After centrifugation, the super-
natant was discarded while the cytoplasmic protein pel-
let was diluted in 150 μl of rehydration buffer (7 M
urea, 2 M thiourea, 2% CHAPS, 0.5% IPG Buffer,
0.002% bromophenol blue). Cytoplasmic protein lysate
was either stored at -80°C for storage or quantified
immediately for subsequent experiments.
Western blot assay
Protein lysate concentration was determined using 2-D
Quant kit (GE Healthcare, USA) according to the manu-
facturer’s instructions. For one-dimensional western
blotting, thirty micrograms protein of each samples were
mixed with 4× sample buffer (50mM Tris-HCl [pH6.8],
2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5mM
EDTA, 0.02% bromophenol blue) before they were loaded
on a 12.5% of SDS-polyacrylamide gel. The proteins were
separated at 100V for approximately 1 hour. Alternatively,
one hundred and fifty micrograms for each protein
samples were separated by two-dimensional (2D) gel
electrophoresis method using 7 cm IPG gel strips
with pH 3–11 NL range (GE Healthcare, USA). After elec-
trophoresis, the stack or sandwich was assembled and
the proteins were transferred onto a nitrocellulose mem-
brane (GE Healthcare, USA) at 250 mA for 1 hour. After
the transfer, the membrane was blocked with Tris buffered
saline buffer consisting 0.1% Tween 20 (TBST) and 5% dry
milk. Subsequently, membranes were incubated with
various primary antibodies and secondary antibodies
diluted using blocking solution. The immune-reacted
proteins were detected via chromogenic method by addition
of DAB substrate onto the membrane to form a protein
band. Anti-pan-Ras, anti-c-Raf, anti-c-Myc, anti-Bcl-2, anti-
Hif-1α, anti-c-Jun/AP-1, anti-p53, anti-Elk1, anti-JNK1/2,
anti-VEGF, goat anti-mouse IgG peroxidase conjugate, and
goat anti-rabbit IgG peroxidase conjugate antibodies were
purchased from Merck Millipore, Germany while anti-RSK
antibody was purchased from Thermo Fischer Scientific,
USA. These antibodies were chosen based on their
essential roles in the pathways modulated by Phyllanthus
as detected using the Cignal Finder Cancer 10-pathway
Reporter Array. A p53 antibody was included to deter-
mine any involvement of p53 pathway in response to
Phyllanthus treatment.
Zymography assay
Zymography is a simple and sensitive technique employed
to study extracellular matrix-degrading proteases such asMMPs based on their substrate specificity and molecular
weight. Briefly, cells were seeded at 1 × 105 cells/well
in a 24-well microtiter plate and treated with increa-
sing concentrations of aqueous (50 μg/ml, IC50,
500 μg/ml) and methanolic (20 μg/ml, IC50, 200 μg/ml)
extracts. After 72 hours incubation, supernatants were col-
lected and stored at -20°C to be used as conditioned media.
The conditioned media was mixed with 2× sample buffer
(0.5M Tris-HCl [pH6.8], 87% glycerol, 10% SDS, 0.1%
bromophenol blue) and subsequently loaded onto a 12.5%
SDS-polyacrylamide gels that had been copolymerized with
0.1% gelatin or 0.2% casein. The gel was then run at ap-
proximately 125V for about 60 minutes. When the proteins
were completely resolved, the gel was washed twice with
renaturing buffer (2.5% Triton X-100) on a shaker at room
temperature, 1 hour for each washing. Next, the gel was in-
cubated with developing buffer (12.1 g Tris, 63 g Tris-HCl,
117 g NaCl, 7.4 g CaCl2, 0.2% Brij35, 1L distilled water)
overnight at 37°C before it was stained with 0.1% Coomasie
blue for 1 hour. Finally, the gel was destained with
destaining solution and the presence of matrix metallo-
proteinase enzyme was indicated as an opaque, unstained
band against a dark blue background.
Human total iNOS and GADPH immunoassay
Inducible Nitric Oxide Synthase (iNOS) is often
upregulated in tumor cells and is an important regulator
for vascularization and angiogenesis. In order to measure
the total iNOS in whole cell, a cell-based ELISA, Human
Total iNOS Immunoassay (R&D Systems, USA) was
performed according to the manufacturer’s instructions.
2-Dimensional gel electrophoresis
Five hundred microgram proteins for A549 cells (treated
and untreated samples) were rehydrated overnight on
13 cm IPG gel strips with pH 3–11 NL range (GE
Healthcare, USA). Strips rehydrated with proteins
were then transferred into IPG chambers and focused
using Ettan IPGphor Isoelectric Focusing unit (GE
Healthcare, USA). Before proceeding with SDS-PAGE,
the strips were first subjected to a two-step equilibration
procedure for 15 minutes each. Firstly, they were equili-
brated with an SDS-PAGE equilibration base buffer added
with 2% (w/v) Dithiothreitol (DTT), followed by equilibra-
tion with 2.5% (w/v) Iodoacetamide (IAA). The strips were
then placed onto a 12.5% SDS-PAGE gel and sealed with
agarose sealing solution. Second dimensional separation
was carried out using Ettan Dalttwelve Separation Unit
(GE Healthcare, USA). The gels were then fixed using gel
fixative solution and stained with Coomasie dye. Finally,
the gel was destained with destaining solution and imaged
using Ettan DIGE Imager (GE Healthcare, USA). Three
independent gels were run for each treatment (n = 3). Gel
images were analyzed using PDQuest 2-D Analysis
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removal, normalization, and automatic matching of the
detected protein spots. Protein spots with more than
2-fold differential expression that showed significant
difference (p < 0.05) were selected and excised for
mass spectrometry analysis.
In-gel enzyme digestion
Protein spots excised from gels were first destained
using 50% acetonitrile (ACN) in 50 mM ammonium
bicarbonate and then incubated with 10mM DTT for
30 minutes at 60°C followed by incubation with
55 mM iodoacetamide for 20 minutes in the dark.
The gel plugs were then washed with 50% ACN in 100
mM ammonium bicarbonate before incubation with 100%
ACN for 15 min on a shaker and dried using SpeedVac.
The dried gel plugs were subsequently incubated with
6 ng/μl trypsin in 50 mM ammonium bicarbonate over-
night at 37°C, vortexed briefly and spun down before 50%
and 100% ACN were added and shaken for 15 minutes
each. The supernatant of each round of extraction was
transferred into a fresh tube before the digested samples
were completely dried using SpeedVac. The samples can
be kept at -20°C until further use. Otherwise, extracted
peptides were concentrated or desalted using ZipTip C18
microcolumns (Merck Millipore, Germany).
MALDI-TOF/TOF mass spectrometry and database
searching
Prior to MALDI-TOF/TOF analysis, 3 μl of each
extracted peptide sample solution was mixed with 3 μl
of alpha-cyano-4-hydroxycinnamic acid (Sigma-Aldrich,
USA) matrix solution dissolved in 50% aqueous ACN
containing 0.1% trifluoroacetic acid (Sigma-Aldrich, USA).
A volume of 0.7 μl of each sample was applied onto a
MALDI plate and was allowed to air dry at room
temperature. Analysis was performed with ABSCIEX 4800
MALDI-TOF/TOF (AB SCIEX, USA) operated in the re-
flector for MALDI-TOF/TOF with fully automated mode
using the 4800 Series Explorer software at an accelerat-
ing voltage of 20 kV. Calibration was performed using
Mass Standards Kit for Calibration of AB SCIEX TOF/
TOF™ Instruments (AB SCIEX, USA). Data collected from
the MALDI-TOF/TOF were submitted to the SwissProt
database using the MASCOT search algorithm (version
2.1.0, Matrix Science, London, UK). Typical search param-
eters for both search engines were defined as follows: tryp-
sin digestion allowing up to two tryptic-mass cleavages,
variable modifications of oxidation and carbamidomethyl,
maximal mass tolerance of 0.1Da, precursor tolerance of
100 ppm, and taxonomy Homo sapiens. Protein scores
greater than 55 were considered significant (p < 0.05). The
protein with the highest number of peptides was consid-
ered as those corresponding to the spot if multipleproteins were identified in a single spot. The proteins iden-
tified were then compared with Uniprot KB/Swiss-Prot
database and grouped according to the Eukaryotic
Orthologous Group of Classifications (COGs).
Data analysis
Results were expressed as the mean ± Standard Error
Mean (SEM) of data obtained from three independent
experiments. All data were analyzed using one way
ANOVA, followed by Dunnett’s test for pairwise
comparison. P < 0.05 was considered statistically significant
for all tests.
Results
Determination of signaling pathways affected by
Phyllanthus
The Cignal Finder Cancer 10-pathway reporter array
was used to simultaneous screen 10 main cellular pathways
that are targeted by Phyllanthus in its anticancer activities.
The pathways included in this array include Wnt, Notch,
p53/DNA damage, TGFβ, Cell cycle/pRb-E2F, NFκB,
Myc/Max, Hypoxia, MAPK/ERK, and MAPK/JNK,
with GFP construct plasmid DNA as the positive control
for this array. As shown in Figure 1A (aqueous extracts-
treated A549) and 1B (methanolic extracts-treated A549),
the expression of GFP construct was consistent in both the
aqueous and methanolic extracts-treated and untreated-
control A549 cells, hence the results obtained were deemed
valid. Upon treatment with various aqueous and methanolic
extracts, most of these pathways’ expression [Myc/Max,
Hypoxia, and MAPK (ERK and JNK)] decreased sig-
nificantly (p < 0.05) except for NFκB which indicate
Phyllanthus probably did not modulate this pathway.
The aqueous Phyllanthus extracts showed better inhibitory
activity on the expression of both MAP kinase pathways,
while the methanolic extracts showed enhanced inhibition
on the expression of Hypoxia and Myc/Max pathways.
Among the four plant species, P. watsonii exhibited
greatest suppression on Hypoxia (aqueous – 60% and
methanolic – 86%), ERK (aqueous – 47% and
methanolic – 27%), and JNK (aqueous – 50% and
methanolic – 26%) pathways, followed by P. urinaria,
P. amarus, and P. niruri.
From the flow cytomery-based cell cycle analysis, we
did not observe cell cycle phase arrest in the A549 cells
treated with Phyllanthus extracts (Figure 2) since the
percentage of gated cells for each cell cycle phases
(G0/G1, S, and G2/M) did not change significantly (p > 0.05)
between the untreated and extracts-treated cells. Thus,
this further explained the low expression level of cell
cycle/pRb-E2F pathway in both the untreated and
treated A549 cells. Nevertheless, the percentages decreased
with a concurrent increase in the percentage of apoptotic
cells (increase in Sub G1 phase) at increasing incubation
Figure 1 Expression level of ten cellular signaling pathways in A549 cells treated with (a) aqueous Phyllanthus extracts and (b)
methanolic Phyllanthus extracts. Error bar indicates the standard error of the mean of three independent experiments. PN – P. niruri,
PU – P. urinaria, PW – P. watsonii, PA – P. amarus. *P < 0.05 vs untreated-control.
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an accumulation of cells at G2/M phase for A549 cells
treated with Cisplatin and Doxorubicin.
Modulation of intracellular signaling molecules
expression by Phyllanthus
In order to confirm the effects of Phyllanthus on MAPK
and Hypoxia pathways, western blots were performed
with available antibodies (Anti-pan-Ras, anti-c-Raf,
anti-c-Myc, anti-Bcl-2, anti-Hif-1α, anti-c-Jun/AP-1,
anti-p53, anti-Elk1, anti-JNK1/2, anti-VEGF, and anti-RSK)
to determine the specific targets of Phyllanthus, whether it
affects during the early or late stages of the signaling
cascade. Figure 3A to I showed the blots for untreated
A549 control as well as the A549 treated with various
aqueous and methanolic extracts while Figure 3K depicts
the expression level of each protein. In untreated A549, the
proteins detected were Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1,
c-Myc, and HIF-1α. The presence of these proteins reflects
the specific involvement of MAPK/ERK and Hypoxia
pathways in regulating the A549 cells’ growth andsurvival. In addition, Bcl-2 protein was also detected
in untreated A549 which explains its role as an
antiapoptotic agent to ensure cell’s survival [27]. Besides
that, FUSE-binding proteins were also detected although
antibody specific to this protein was not included in this
experiment. This might probably be attributed to its role
for proper regulation of the c-Myc protooncogene [28], as
it has a certain percentage of similarity with c-Myc protein
and was therefore detected when c-Myc antibody was
used. As expected, most of these proteins’ expression
decreased when A549 was treated with various Phyllanthus
extracts. Among the four species, P. urinaria showed
better inhibition on those proteins, followed by
P. amarus, P. watsonii, and P. niruri for both the aque-
ous and methanolic extracts. The expression of Pan-Ras
and Elk-1 proteins were only mildly affected as compared
to the other proteins and p53 expression was hardly seen
in both the treated and untreated A549 cells via western
blot technique, thus confirming the findings obtained
from the previous cancer 10-pathway array which demon-
strated low p53 expression in A549.
Figure 2 Percentage of cell cycle phase distribution of A549 cells treated with both aqueous and methanolic Phyllanthus extracts and
standard drugs at their IC50 (μg/ml) concentrations for (a) 24 hours, (b) 48 hours, and (c) 72 hours. Error bar indicates the standard error
of the mean of three independent experiments. Aq – Aqueous, MeOH - Methanolic, Control – Untreated cells. *P < 0.05 vs untreated-control.
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expression by Phyllanthus
MMPs play an important role during tumor metastasis and
angiogenesis since its expression level is often correlated
with the tumor invasiveness [29]. Among the variety ofMMPs, MMP2, MMP7, and MMP9 were more commonly
associated with cancer metastasis as they have the ability to
degrade collagen type IV which is the major component of
basement membrane [23,25]. MMP7 probably plays a
greater role in A549 metastasis since its expression was
Figure 3 Expression level of Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1, c-Myc, HIF-1α, Bcl-2, and FUSE-binding proteins in (a) untreated A549 cells
and cells treated with (b) aqueous P. niruri, (c) aqueous P. urinaria, (d) aqueous P. watsonii, (e) aqueous P. amarus, (f) methanolic P. niruri,
(g) methanolic P. urinaria, (h) methanolic P. watsonii, and (i) methanolic P. amarus, (j) Expression level of VEGF in untreated-control and
Phyllanthus-treated A549 cells, (k) Percentage of individual protein expression analysed using Image J software.
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MMP2 and MMP9. Nonetheless, their expressions de-
creased in a dose-dependent manner as shown by the
untreated-control and Phyllanthus-treated bands’ intensity
in Figure 4. However, the bands for proMMPs with their
respective MMPs were not well separated in the zymo-
gram, hence leading to the inability to distinguish between
the active and latent MMPs. Methanolic Phyllanthusextracts demonstrated greater inhibition on the MMPs’
expression than aqueous extracts, with P. urinaria show-
ing the greatest inhibitory activity compared to the other
Phyllanthus species.
Inhibition of iNOS and VEGF expression by Phyllanthus
Angiogenesis or blood vessel formation is the key process
in the survival and metastasis of tumors in a hypoxic
Figure 4 Matrix metalloproteinases (MMPs) expression level in A549 cells treated with (a and c) aqueous Phyllanthus extracts and
(b and d) methanolic Phyllanthus extracts. M – protein marker, C – untreated control, L – treatment at 200 μg/ml and 20 μg/ml for aqueous
and methanolic extracts respectively, I – treatment at their respective IC50 concentrations, H – treatment at 500 μg/ml and 50 μg/ml for aqueous
and methanolic extracts respectively, PN – P. niruri, PU – P. urinaria, PW – P. watsonii, PA – P. amarus.
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stabilization will lead to the activation of various genes
including vascular endothelial growth factor (VEGF) and
inducible nitric oxide synthases (iNOS) [30]. This was
verified with the high expression of both VEGF and iNOS
detected in the untreated-control A549 cells (Figure 5)
using a cell-based ELISA assay. Upon treatment with vari-
ous Phyllanthus, both the aqueous and methanolic extracts
for all four species were observed to demonstrate
inhibition on iNOS, whereby most of their expres-
sions dropped markedly to approximately 20% except
for methanolic P. urinaria which retained 40% of
iNOS expression. Generally, P. urinaria (78% reduc-
tion) scored highest iNOS inhibition among aqueous
extracts while P. watsonii (82% reduction) exhibited
strongest activity among methanolic extracts. This
suppression ability was comparable to Cisplatin and
Doxorubicin with 15% and 10% iNOS expression that
remained after treatment respectively.
On the other hand, methanolic Phyllanthus extracts
showed better suppression of VEGF expression with
60 – 80% reduction compared to aqueous extracts
which caused 20 – 50% reduction. In addition to this
ELISA assay, expression of VEGF was also confirmed
by western blot assay when VEGF expression dropped
to 30 – 80% after A549 cells were treated with aqueous
and methanolic Phyllanthus extracts (Figure 3J and K).
Among the four species, methanolic P. amarus
displayed better VEGF repression with only 20%
VEGF expression. Meanwhile, P. urinaria exhibited
slightly weaker capability to inhibit VEGF expression
with 25% (aqueous) and 65% (methanolic) reduction
respectively.Differentially expressed proteins in Phyllanthus-treated
A549
Figure 6 showed representative 2D-PAGE gels for untreated-
control, aqueous P. watsonii-treated, and methanolic
P. watsonii-treated A549 samples. Two-dimensional
gel electrophoresis proteomic analysis picked out 68
and 79 protein spots differentially expressed in aqueous
and methanolic extracts-treated groups respectively.
Subsequent mass spectrometry analysis and database
examination using MASCOT identified 52 protein spots
significantly downregulated by aqueous Phyllanthus
extracts as listed in Table 2. These protein spots were
further categorized according to Clusters of Orthologous
Groups (COGs) classification and majority of them fell into
the category of post-translational modification, protein
turnover, and chaperones, followed by intracellular traffick-
ing, secretion, and vesicular transport, cytoskeleton, as well
as energy production and conversion (Figure 7A). On the
other hand, methanolic Phyllanthus extracts significantly
suppressed 64 proteins as tabulated in Table 3. Most of
these proteins fell into the category of signal transduction
mechanisms, transcription, defense mechanisms, amino
acid transport and metabolism, as well as secondary metab-
olites biosynthesis, transport, and catabolism (Figure 7B).
The negative (-) symbol in both Tables 2 and 3 signified
suppression of the proteins and a value of 1.00 indicates the
complete absence of this protein in the Phyllanthus-treated
sample as compared to the untreated-control sample and
the degree of suppression reduces as the value increases.
Discussion
Numerous reports describe poor therapeutic efficacy
and prognostic survival for lung malignancy which is
Figure 5 Expression level of (a) iNOS and (b) VEGF in untreated and Phyllanthus-treated A549 cells. APN - aqueous P. niruri, APU - aqueous
P. urinaria, APW - aqueous P. watsonii, APA - aqueous P. amarus, MPN - methanolic P. niruri, MPU - methanolic P. urinaria, MPW - methanolic P. watsonii,
MPA - methanolic P. amarus, CIS – Cisplatin, DOX – Doxorubicin. Error bar indicates the standard error of the mean of three independent experiments.
P < 0.05 for all extracts-treated A549 compared to untreated-control A549.
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well as to induce angiogenesis. Therefore, it is crucial to
develop novel antimetastatic drugs with low toxicity and
high efficacy [17,29]. In our previous study, aqueous and
methanolic extracts of Phyllanthus was shown to possess
the potential to inhibit growth of A549 in a time- and
dose-dependent manner with minimal toxicity to the
normal lung epithelial (NL20) cells. Besides that,
Phyllanthus suppressed the invasion, migration, and
reattachment of A549 in a dose-dependent manner and
was capable of inducing apoptosis in conjunction with
its antimetastastic action [17]. However, the underlying
mechanisms that confer their antimetastatic and
apoptosis-inducing abilities were uncertain.In the current study, numerous differentially expressed
proteins were being identified in A549 cells in response
to Phyllanthus treatments using 2DE-based proteomic
approach. Both aqueous and methanolic Phyllanthus
extracts modulate expression of different set of proteins
[17]. Among the four Phyllanthus species, P. urinaria
generally demonstrated the greatest activity on A549,
closely followed by P. watsonii, P. amarus, and P. niruri.
This could be delineated by the higher number of
polyphenol compounds present in both the aqueous
(9 out of 10 polyphenols) and methanolic (3 out of 4
polyphenols) P. urinaria extracts [17,20], hence having a
higher capability to cause antimetastatic activities on
A549. Some of those proteins were represented by more
Figure 6 Representative 2D-PAGE gels for (a and b) untreated-control A549 and its aqueous P. watsonii-treated A549, as well as
(c and d) untreated-control A549 and its methanolic P. watsonii-treated A549.
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forms of the same protein as a result of post-translational
modification [14].
Therefore, protein turnover, chaperones, and post-
translational modification are indeed crucial to produce
many variants of the common amino acid that possess
distinctive structures and functions essential for tumor
growth [31,32]. In order to ensure uninterrupted cell
growth, continuous protein synthesis is necessary.
Therefore, 40S ribosomal protein is normally upregulated
in the tumor cell as it is an essential component of the
higher eukaryotic ribosome that is necessary for proper
protein translational function [33]. Eukaryotic translation
initiation factor 3 subunit 12 is another important
component as it binds to poly(A)-binding protein to
initiate translation process [34]. Protein folding is the
subsequent critical process upon successful protein
translation to ensure formation of functional proteins
and this step usually requires the presence of chaperone
proteins. One of these proteins is Hsp60 whose primary
role is to guide the folding of mitochondrial proteins
while facilitating proteolytic degradation of denatured
or misfolded proteins in an ATP-dependent manner
[35]. Other chaperones include peptidyl-prolyl cis-trans
isomerase A and T-complex protein 1 subunit epsilon
which also assists the proper folding of proteins [36,37].
Besides facilitating protein folding, chaperones also
guide the proper assembly of other proteins for them to
carry out their activities. An important example is stress-
induced phosphoprotein 1 that facilitates association of
molecular chaperones Hsp70 and Hsp 90 which have beenimplicated in MMP2 activity that lead to increased
invasiveness [38]. Downregulation of these proteins by
Phyllanthus is therefore one of the key processes for
A549 growth and metastasis inhibition by reducing
functional protein synthesis and suppression of MMP
expression. In addition to MMP2, suppression of other
MMPs in response to Phyllanthus treatment was also
observed including MMP7 and MMP9. Tumor invasion
and metastasis depends largely on the integrity of the
basement membrane which is frequently destroyed by a
number of proteolytic enzymes such as MMPs in order to
access the vasculature to develop distant metastases [22].
Among the MMPs family, MMP2 and MMP9 were more
commonly associated with cancer invasion and metastasis
since they had been known to be able to degrade type IV
collagen-rich basement membrane of vessel wall [23].
MMP7 (28 kDa) is another member of the MMP family
with broad substrate specificity against ECM components
such as elastin, type IV collagen, fibronectin, vitronectin,
aggrecan, and proteoglycans [25]. Reduced expression of
these MMP enzymes explains the decreased aggressiveness
of A549 cells’ invasion upon treatment with Phyllanthus.
A constant activation of various growth-promoting
signaling pathways is also required to ensure continuous
cell growth and survival. This activation often involves
numerous proteins which require some form of modifi-
cations such as phosphorylation for their biological role.
Thus, post-translational modification process that alters
the proteins properties is important [39,40]. The first
step for pathway activation often requires the presence
of receptor molecules on the cell surface for ligand
Table 2 Identified proteins of A549 downregulated (-) in the presence of aqueous Phyllanthus extracts
Spot ID Possible proteins Fold change UNIPROT KB/SWISS-PROT
Acc. Number
Database
APN APU APW APA
1 Actin, cytoplasmic 1 −0.81 −0.88 −0.95 −0.84 P60709 MASCOT;UNIPROT KB/SWISS-PROT;COGS
2 Nicotinamide N-methyltransferase −0.50 N/A −0.28 −0.10 P40261 MASCOT;UNIPROT KB/SWISS-PROT;COGS
3 Alpha-Enolase −0.62 −0.57 −0.48 −0.58 P06733 MASCOT;UNIPROT KB/SWISS-PROT;COGS
4 Proteasome subunit beta type 3 −1.00 −0.20 N/A −1.00 P49720 MASCOT;UNIPROT KB/SWISS-PROT;COGS
5 Retinal dehydrogenase 1 −0.23 N/A −0.13 N/A P00352 MASCOT;UNIPROT KB/SWISS-PROT;COGS
6 Galectin-1 −1.00 −0.13 −0.57 −0.38 P09382 MASCOT;UNIPROT KB/SWISS-PROT;COGS
7 Heat-shock protein beta-1 −0.12 −0.22 −0.32 −0.10 P04792 MASCOT;UNIPROT KB/SWISS-PROT;COGS
8 Glyceraldehyde-3-phosphate dehydrogenase −0.30 −0.93 −0.99 −0.91 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS
9 Eukaryotic translation initiation factor 5A-1 −0.32 −0.39 −0.27 −0.80 P63241 MASCOT;UNIPROT KB/SWISS-PROT;COGS
10 60 kDa heat shock protein, mitochondrial precursor −0.46 −0.82 −0.90 −0.75 P10809 MASCOT;UNIPROT KB/SWISS-PROT;COGS
11 Glutathione transferase omega-1 N/A −0.45 N/A −0.22 P78417 MASCOT;UNIPROT KB/SWISS-PROT;COGS
12 Proteasome activator complex subunit 1 −0.19 −0.18 N/A −1.00 Q06323 MASCOT;UNIPROT KB/SWISS-PROT;COGS
13 Annexin A4 −0.29 −0.29 −0.21 −0.65 P09525 MASCOT;UNIPROT KB/SWISS-PROT;COGS
14 Vimentin −0.91 −0.82 −0.24 −0.79 P08670 MASCOT;UNIPROT KB/SWISS-PROT;COGS
15 Peptidyl-prolyl cis-trans isomerase A −0.13 −0.36 −1.00 −0.42 P62937 MASCOT;UNIPROT KB/SWISS-PROT;COGS
16 Peptidyl-prolyl cis-trans isomerase A −1.00 −1.00 −0.32 N/A P62937 MASCOT;UNIPROT KB/SWISS-PROT;COGS
17 Glyceraldehyde-3-phosphate dehydrogenase −1.00 −0.50 −1.00 −0.71 P04406 MASCOT;UNIPROT KB/SWISS-PROT;COGS
18 Voltage-dependent anion-selective channel protein 1 −0.37 −0.19 −0.20 N/A P21796 MASCOT;UNIPROT KB/SWISS-PROT;COGS
19 Tubulin alpha-8 chain −0.80 −0.37 N/A −0.80 Q9NY65 MASCOT;UNIPROT KB/SWISS-PROT;COGS
20 Protein FAM24B precursor −0.51 −0.54 −0.66 −0.88 Q8N5W8 MASCOT;UNIPROT KB/SWISS-PROT;COGS
21 Interferon alpha-6 precursor −0.41 N/A −0.38 −0.75 P05013 MASCOT;UNIPROT KB/SWISS-PROT;COGS
22 ATP-dependent DNA helicase Q5 −1.00 −1.00 −0.93 −0.79 O94762 MASCOT;UNIPROT KB/SWISS-PROT;COGS
23 Sorting nexin-3 −0.25 −1.00 −1.00 −1.00 O60493 MASCOT;UNIPROT KB/SWISS-PROT;COGS
24 Gap junction beta-5 protein −0.36 −0.16 −0.32 −0.41 O95377 MASCOT;UNIPROT KB/SWISS-PROT;COGS
25 40S ribosomal protein S19 −0.30 −0.30 −0.15 −0.38 P39019 MASCOT;UNIPROT KB/SWISS-PROT;COGS
26 Stress-70 protein, mitochondrial precursor −0.19 −0.22 N/A N/A P38646 MASCOT;UNIPROT KB/SWISS-PROT;COGS
27 Actin-related protein 2/3 complex subunit 5 −1.00 −1.00 −1.00 −1.00 O15511 MASCOT;UNIPROT KB/SWISS-PROT;COGS
28 Sorting nexin-3 −0.36 −0.35 −0.37 −1.00 O60493 MASCOT;UNIPROT KB/SWISS-PROT;COGS
29 Complement receptor type 1 precursor −0.19 N/A −0.41 −1.00 P17927 MASCOT;UNIPROT KB/SWISS-PROT;COGS
30 40S ribosomal protein S24 −1.00 −1.00 −1.00 −1.00 P62847 MASCOT;UNIPROT KB/SWISS-PROT;COGS
31 Corticotropin-lipotropin precursor −0.73 −0.88 −1.00 −1.00 P01189 MASCOT;UNIPROT KB/SWISS-PROT;COGS
























Table 2 Identified proteins of A549 downregulated (-) in the presence of aqueous Phyllanthus extracts (Continued)
33 Peroxiredoxin-1 −0.08 −0.56 −1.00 −0.33 Q06830 MASCOT;UNIPROT KB/SWISS-PROT;COGS
34 Protein memo −0.95 −0.88 −0.56 −0.47 Q9Y316 MASCOT;UNIPROT KB/SWISS-PROT;COGS
35 Voltage-dependent anion-selective channel protein 2 −1.00 −0.31 −0.46 −0.21 P45880 MASCOT;UNIPROT KB/SWISS-PROT;COGS
36 Thioredoxin-dependent peroxide reductase, mitochondrial precursor −0.28 −0.19 −0.27 N/A P30048 MASCOT;UNIPROT KB/SWISS-PROT;COGS
37 RuvB-like 2 −0.24 N/A −0.43 −0.11 Q9Y230 MASCOT;UNIPROT KB/SWISS-PROT;COGS
38 EF-hand domain-containing protein 2 −0.36 −0.17 −0.37 −0.29 Q5JST6 MASCOT;UNIPROT KB/SWISS-PROT;COGS
39 T-complex protein 1 subunit epsilon −0.89 N/A −0.20 −0.97 P48643 MASCOT;UNIPROT KB/SWISS-PROT;COGS
40 Stress-induced-phosphoprotein 1 −0.54 −0.62 −0.44 −0.21 P31948 MASCOT;UNIPROT KB/SWISS-PROT;COGS
41 Retinal dehydrogenase 1 −0.33 −0.79 −0.58 −0.61 P00352 MASCOT;UNIPROT KB/SWISS-PROT;COGS
42 Prostaglandin E synthase 3 −0.26 −0.36 −0.97 −0.16 Q15185 MASCOT;UNIPROT KB/SWISS-PROT;COGS
43 Trypsin-1 precursor −0.37 −1.00 −0.28 −0.35 P07477 MASCOT;UNIPROT KB/SWISS-PROT;COGS
44 Serpin B9 −0.51 −0.14 −0.21 −0.51 P50453 MASCOT;UNIPROT KB/SWISS-PROT;COGS
45 N-acylneuraminate cytidylyltransferase −0.64 −0.57 −0.50 −0.28 Q8NFW8 MASCOT;UNIPROT KB/SWISS-PROT;COGS
46 Cofilin-1 −0.76 N/A −0.85 −0.38 P23528 MASCOT;UNIPROT KB/SWISS-PROT;COGS
47 ADP-ribosylation factor 1 −1.00 −0.21 −0.15 −1.00 P84077 MASCOT;UNIPROT KB/SWISS-PROT;COGS
48 Fructose-bisphosphate aldolase A −1.00 −1.00 −1.00 −1.00 P04075 MASCOT;UNIPROT KB/SWISS-PROT;COGS
49 Sorting nexin-3 −1.00 −1.00 −1.00 −1.00 O60493 MASCOT;UNIPROT KB/SWISS-PROT;COGS
50 Phosphoglycerate mutase 1 −1.00 −1.00 −1.00 −1.00 P18669 MASCOT;UNIPROT KB/SWISS-PROT;COGS
51 Triosephosphate isomerase −1.00 −1.00 −1.00 −1.00 P60174 MASCOT;UNIPROT KB/SWISS-PROT;COGS
52 Eukaryotic translation initiation factor 5A-1 −1.00 −1.00 −1.00 −1.00 P63241 MASCOT;UNIPROT KB/SWISS-PROT;COGS
The negative (-) symbol signified suppression of the proteins and a value of 1.00 indicates the complete absence of this protein in the aqueous Phyllanthus-treated sample as compared to the untreated-control sample and
























Figure 7 Clusters of Orthologous Groups (COGs) classification of identified proteins in A549 cells treated with (a) aqueous Phyllanthus
extracts and (b) methanolic Phyllanthus extracts.
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http://www.biomedcentral.com/1472-6882/13/271binding. So, guanine nucleotide-binding protein, putative
Ras-related protein Rab-42, and GTPase HRas precursor
protein which can be broadly grouped as G-proteins, as
well as probable G-protein coupled receptor 179 precur-
sor expressions are usually elevated in the tumor cells to
accommodate the large amount of extracellular signals
to be transduced into the cells [41]. Both G-protein
coupled receptor and G-proteins form the G-protein
mediated signaling cascade whereby binding of ligands
to receptors will lead to activation of G-proteins by pro-
moting GDP/GTP exchange, which in turn regulates
many effector molecules such as proteins kinases [41].
Therefore, the subsequent upregulated protein in thetumor cell is serine/threonine-protein kinase 6 which is
a family of kinases including MAP kinase [42], which
functions to turn on the downstream kinases via serine/
threonine phosphorylation [43]. Suppression of these cell
signaling proteins by Phyllanthus could therefore decelerate
or stop the constitutive activation of the growth-promoting
pathways such as MAP kinase and hypoxia.
ERK1/2 pathway is one of the MAP kinase subgroup
which was frequently found to be inhibited in A549 to
repress cells’ continuous growth and metastasis. In a study
by Shih et al. [21], α-tomatine found in tomatoes was shown
to be capable of inactivating extracellular signal-regulated
kinase 1 and 2 (ERK1/2) pathway to inhibit metastasis
Table 3 Identified proteins of A549 downregulated (-) in the presence of methanolic Phyllanthus extracts
Spot ID Possible proteins Fold change UNIPROT KB/SWISS-PROT
Acc. Number
Database
MPN MPU MPW MPA
1 Protein S100-A8 −0.47 −0.10 −0.48 −0.55 P05109 MASCOT;UNIPROT KB/SWISS-PROT;COGS
2 Transmembrane protein 35 −0.82 −0.78 −1.00 −0.50 Q53FP2 MASCOT;UNIPROT KB/SWISS-PROT;COGS
3 Adenylate kinase isoenzyme 6 −0.32 −0.62 −0.81 −0.73 Q9Y3D8 MASCOT;UNIPROT KB/SWISS-PROT;COGS
4 Peroxiredoxin-1 −0.78 −1.00 −1.00 −1.00 Q06830 MASCOT;UNIPROT KB/SWISS-PROT;COGS
5 Prolactin-releasing peptide precursor −0.59 −0.29 −0.23 −0.39 P81277 MASCOT;UNIPROT KB/SWISS-PROT;COGS
6 Putative protein SSX6 −0.46 −0.96 −1.00 −0.75 Q7RTT6 MASCOT;UNIPROT KB/SWISS-PROT;COGS
7 Glutathione synthetase −0.38 −0.79 −1.00 −0.51 P48637 MASCOT;UNIPROT KB/SWISS-PROT;COGS
8 Nucleoside diphosphate-linked moiety X motif 16 −0.61 −0.63 −0.98 −0.94 Q3MHX9 MASCOT;UNIPROT KB/SWISS-PROT;COGS
9 E3 ubiquitin-protein ligase ZNRF1 N/A N/A −0.47 −0.36 Q8ND25 MASCOT;UNIPROT KB/SWISS-PROT;COGS
10 DNA-directed RNA polymerase II 16 kDa polypeptide −0.46 −0.59 −0.43 −0.93 Q9VEA5 MASCOT;UNIPROT KB/SWISS-PROT;COGS
11 39S ribosomal protein L40, mitochondrial precursor −1.00 −1.00 −1.00 −1.00 Q9NQ50 MASCOT;UNIPROT KB/SWISS-PROT;COGS
12 Zinc finger protein 174 −1.00 −1.00 −1.00 −1.00 Q15697 MASCOT;UNIPROT KB/SWISS-PROT;COGS
13 Probable G-protein coupled receptor 179 precursor −0.21 −0.15 −1.00 N/A Q6PRD1 MASCOT;UNIPROT KB/SWISS-PROT;COGS
14 Histatin-1 precursor −0.24 −0.66 −0.78 −0.27 P15515 MASCOT;UNIPROT KB/SWISS-PROT;COGS
15 U6 snRNA-associated Sm-like protein LSm5 −0.33 −0.57 −0.19 −0.54 Q9Y4Y9 MASCOT;UNIPROT KB/SWISS-PROT;COGS
16 Bcl-2-like protein 11 −0.25 −1.00 −1.00 −0.70 O43521 MASCOT;UNIPROT KB/SWISS-PROT;COGS
17 Contactin-2 precursor −0.29 −0.60 −0.42 −0.39 Q02246 MASCOT;UNIPROT KB/SWISS-PROT;COGS
18 Bis(5′-adenosyl)-triphosphatase −1.00 −1.00 N/A −1.00 P49789 MASCOT;UNIPROT KB/SWISS-PROT;COGS
19 Trypsin-1 precursor −1.00 −0.98 −1.00 −1.00 P07477 MASCOT;UNIPROT KB/SWISS-PROT;COGS
20 Proliferating cell nuclear antigen −1.00 −1.00 −1.00 −1.00 P12004 MASCOT;UNIPROT KB/SWISS-PROT;COGS
21 Endoplasmin precursor N/A −1.00 −1.00 −0.37 P14625 MASCOT;UNIPROT KB/SWISS-PROT;COGS
22 Eukaryotic translation initiation factor 3 subunit 12 −1.00 −1.00 −1.00 −1.00 Q9UBQ5 MASCOT;UNIPROT KB/SWISS-PROT;COGS
23 Serine/threonine-protein kinase 6 −1.00 −0.96 −0.19 −1.00 O14965 MASCOT;UNIPROT KB/SWISS-PROT;COGS
24 Phenylalanyl-tRNA synthetase beta chain −1.00 −1.00 −1.00 −1.00 Q9NSD9 MASCOT;UNIPROT KB/SWISS-PROT;COGS
25 Neutrophil defensin 1 precursor −0.78 −0.49 −0.20 −0.88 P59665 MASCOT;UNIPROT KB/SWISS-PROT;COGS
26 Proto-oncogene protein Wnt-3 precursor −0.58 N/A −0.34 −0.55 P56703 MASCOT;UNIPROT KB/SWISS-PROT;COGS
27 Putative Ras-related protein Rab-42 −1.00 N/A −0.97 −0.80 Q8N4Z0 MASCOT;UNIPROT KB/SWISS-PROT;COGS
28 UPF0404 protein C11orf59 −0.19 −0.36 N/A −0.36 Q6IAA8 MASCOT;UNIPROT KB/SWISS-PROT;COGS
29 Neutrophil defensin 1 precursor −0.31 −0.25 −1.00 −0.87 P59665 MASCOT;UNIPROT KB/SWISS-PROT;COGS
30 Agouti-signaling protein precursor −0.33 −0.67 −0.67 N/A P42127 MASCOT;UNIPROT KB/SWISS-PROT;COGS
31 DNA-directed RNA polymerase II 16 kDa polypeptide −0.42 −0.48 −0.48 −0.45 Q9VEA5 MASCOT;UNIPROT KB/SWISS-PROT;COGS
























Table 3 Identified proteins of A549 downregulated (-) in the presence of methanolic Phyllanthus extracts (Continued)
33 Transcription elongation factor B polypeptide 1 −0.58 −0.59 −0.56 −0.79 Q15369 MASCOT;UNIPROT KB/SWISS-PROT;COGS
34 Metallothionein-1M −0.55 −0.52 −0.48 −0.48 Q8N339 MASCOT;UNIPROT KB/SWISS-PROT;COGS
35 GTPase HRas precursor −0.60 −0.66 −0.59 −0.61 P01112 MASCOT;UNIPROT KB/SWISS-PROT;COGS
36 Neuromedin-B precursor −0.24 −0.32 −0.23 −0.34 P08949 MASCOT;UNIPROT KB/SWISS-PROT;COGS
37 Protein-tyrosine sulfotransferase 2 −0.36 N/A N/A −0.33 O60704 MASCOT;UNIPROT KB/SWISS-PROT;COGS
38 Apolipoprotein A-II precursor −0.23 −0.23 −0.13 −0.37 P02652 MASCOT;UNIPROT KB/SWISS-PROT;COGS
39 ADP-ribosylation factor-like protein 6 −0.58 −0.52 −1.00 −0.29 Q9H0F7 MASCOT;UNIPROT KB/SWISS-PROT;COGS
40 Alpha-enolase −0.27 −0.51 N/A −0.56 P06733 MASCOT;UNIPROT KB/SWISS-PROT;COGS
41 Serine/threonine-protein phosphatase PP1-beta catalytic subunit −1.00 −1.00 −0.44 −0.71 P62140 MASCOT;UNIPROT KB/SWISS-PROT;COGS
42 N-acylneuraminate cytidylyltransferase −1.00 −1.00 −1.00 −1.00 Q8NFW8 MASCOT;UNIPROT KB/SWISS-PROT;COGS
43 Inosine triphosphate pyrophosphatase −1.00 −1.00 −1.00 −1.00 Q9BY32 MASCOT;UNIPROT KB/SWISS-PROT;COGS
44 Alkyldihydroxyacetonephosphate synthase −1.00 −0.55 −1.00 −1.00 O00116 MASCOT;UNIPROT KB/SWISS-PROT;COGS
45 Microsomal signal peptidase 18 kDa subunit −1.00 −0.57 −1.00 −1.00 P67812 MASCOT;UNIPROT KB/SWISS-PROT;COGS
46 Tumor suppressor candidate 2 −0.89 −0.75 −0.67 −0.21 O75896 MASCOT;UNIPROT KB/SWISS-PROT;COGS
47 Metallothionein-2 −0.71 −0.17 −0.14 −0.53 P02795 MASCOT;UNIPROT KB/SWISS-PROT;COGS
48 Protein FAM3B precursor −0.57 −0.48 −0.39 −0.48 P58499 MASCOT;UNIPROT KB/SWISS-PROT;COGS
49 Metallothionein-1H −0.52 −0.48 N/A −0.29 P80294 MASCOT;UNIPROT KB/SWISS-PROT;COGS
50 Metallothionein-2 −0.34 −0.59 −0.49 −1.00 P02795 MASCOT;UNIPROT KB/SWISS-PROT;COGS
51 Protein BEX5 −0.48 −0.33 −0.30 −0.48 Q5H9J7 MASCOT;UNIPROT KB/SWISS-PROT;COGS
52 DNA-directed RNA polymerase II 16 kDa polypeptide −1.00 −1.00 −1.00 −1.00 Q9VEA5 MASCOT;UNIPROT KB/SWISS-PROT;COGS
53 Cytochrome c oxidase polypeptide VIa-liver, mitochondrial precursor −0.93 −0.24 −1.00 −0.14 P12074 MASCOT;UNIPROT KB/SWISS-PROT;COGS
54 Putative protein 15E1.2 N/A −0.94 −1.00 −0.30 - MASCOT;COGS
55 Voltage-dependent anion-selective channel protein 1 −0.15 −0.28 −0.35 −0.27 P21796 MASCOT;UNIPROT KB/SWISS-PROT;COGS
56 Voltage-dependent anion-selective channel protein 1 −0.47 −0.13 −1.32 N/A P21796 MASCOT;UNIPROT KB/SWISS-PROT;COGS
57 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit −0.64 −0.76 −0.43 −0.32 P62136 MASCOT;UNIPROT KB/SWISS-PROT;COGS
58 Acetyl-CoA acetyltransferase, cytosolic −0.95 −1.00 −0.17 −1.00 Q9BWD1 MASCOT;UNIPROT KB/SWISS-PROT;COGS
59 Glutathione synthetase −0.50 −0.45 −0.38 −0.61 P48637 MASCOT;UNIPROT KB/SWISS-PROT;COGS
60 Actin-related protein 10 −0.94 −0.70 −0.13 −0.73 Q9NZ32 MASCOT;UNIPROT KB/SWISS-PROT;COGS
61 Enteropeptidase precursor −0.63 −0.19 −1.00 −0.70 P98073 MASCOT;UNIPROT KB/SWISS-PROT;COGS
62 Metallothionein-1L −0.86 −0.79 −0.96 −0.44 Q93083 MASCOT;UNIPROT KB/SWISS-PROT;COGS
63 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-5-like subunit −1.00 −1.00 −1.00 −1.00 P63218 MASCOT;UNIPROT KB/SWISS-PROT;COGS
64 Small inducible cytokine B14 precursor −1.00 −1.00 −1.00 −1.00 O95715 MASCOT;UNIPROT KB/SWISS-PROT;COGS
The negative (-) symbol signified suppression of the proteins and a value of 1.00 indicates the complete absence of this protein in the methanolic Phyllanthus-treated sample as compared to the untreated-control
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http://www.biomedcentral.com/1472-6882/13/271occurrence in A549 cell line. Similarly, A549 metastasis was
also inhibited by Silibinin isolated from Silybum marianum
which suppresses ERK1/2 pathway that led to a reduced
expression of MMP2 and u-PA concomitantly with a
significant inhibition on cell invasion [22]. Indeed,
our study also showed that Phyllanthus inhibit A549
metastasis via targeting specifically ERK1/2 pathway.
ERK1/2 module is often thought as a linear pathway
since ERK is the effector of an evolutionarily conserved sig-
naling component that is triggered exclusively by the Raf
serine/threonine kinases [44,45]. Therefore, Phyllanthus
might possibly downregulate Raf protein at the early stage
of the pathway, resulting in the subsequent suppression of
other proteins’ expression down the pathway. As a result,
various biological activities controlled by ERK1/2 pathway
to increase cell growth and malignancy are repressed,
including regulation of transcriptional, cell cycle, apoptosis,
and metastasis [46].
Transcription is an important biological activity in a cell
as it is the first step for the transmission of genetic
information from DNA into RNA to be translated
into proteins [47]. With the suppression of the essential
transcriptional proteins for eukaryotic chromosomal
DNA replication such as DNA-directed RNA polymerase
II 16kDa polypeptide, transcription elongation factor B
polypeptide 1, and proliferating cell nuclear antigen,
transcription initiation and elongation process becomes
inefficient [48,49]. Besides that, zinc finger protein 174 is a
DNA binding protein that acts as a cofactor for transcrip-
tion factor. Its downregulation will lead to increased tran-
scription of proteins such as E-cadherin which in turn
represses cell invasion [50]. Also, cell cycle disorder plays
a critical role in cancer progression. So, modulation of cell
cycle by phytochemicals from natural product sources is
gaining worldwide attention to control carcinogenesis
[51]. However, our findings showed that cell cycle pathway
was not modulated with the flow cytometric data showing
insignificant shifts in each cell cycle phases for the cells
treated with Phyllanthus extracts. Hence, cell cycle arrest
was ruled out as one of the mechanism of actions of the
extracts. Since Phyllanthus do not inflict cell cycle arrest
on A549, the only approach to inhibit A549′s continuous
growth is by causing toxicity. As showed in the previous
study, Phyllanthus does induce apoptosis in A549 with
more than three folds increase of caspases-3 and -7, the
presence of DNA-fragmentation and TUNEL-positive
cells [17]. In order to determine whether Phyllanthus
induces extrinsic or intrinsic apoptotic pathway, Bcl-2
expression was examined using immunoblot analysis since
it is one of the main regulators of the mitochondrial outer
membrane permeabilization which initiates intrinsic
apoptotic cell death [52,53]. The data obtained agrees
with our previous hypothesis that Phyllanthus probably
activates the intrinsic pathway of apoptosis by inhibitingantiapoptotic Bcl-2 protein to release cytochrome c for
caspases activation. In addition to this, proteomic analysis
also observed downregulation of Bcl-2-like protein 11
which is similar to Bcl-2 protein that has a role as an
antiapoptotic protein [52]. Apart from that, suppressing
MAP kinases and its downstream factors such as AP-1
have been shown to decrease MMPs expression and sub-
sequently inhibit various pathological processes such as
tumor invasion, adhesion, metastasis, and angiogenesis
[22,24]. This is in accordance with results from the current
study that showed decreased ERK1/2 pathway and MMPs
activity by Phyllanthus which led to inhibition of A549 me-
tastasis. Moreover, Phyllanthus extracts also suppressed
cytoskeletal proteins such as actin, vimentin, tubulin alpha
chain, actin-related protein, and cofilin-1/2. Besides being
the components of the cytoskeleton, both actin and
tubulin-binding proteins are also mediators of motility [8].
Structure, conformational dynamics, and mechanical prop-
erties of actin filaments are mainly controlled by cofilin
[54]. Meanwhile, vimentin constitutes the intermediate
filaments of the cytoskeleton which stabilizes cytoskeletal
interactions as well as affecting cell motility and movement.
Elevated expression of vimentin in several invasive cell lines
suggests the possibility of it being a representative marker
for epithelial to mesenchymal transition [38]. Therefore, the
significant inhibitory effects of Phyllanthus on the A549
cell’s cytoskeleton most probably involve the alteration of
the microfilament organization and function, therefore
suppressing motility and metastasis [55].
Hypoxia is largely perceived as another major obstacle
to cancer therapy as increasing evidence in the cancer
therapy-related literatures suggests the involvement of
proangiogenic factors in the progression of lung tumori-
genesis [7]. Angiogenesis is essential for tumor growth
and survival due to the imbalance of nutrient and
oxygen supplies to solid tumors larger than 1 mm3,
resulting in tumor hypoxia [56]. One of the major regu-
latory component which responds to hypoxia to ensure
cell survival and to promote angiogenesis is HIF-1α
[2,7]. Therefore, it could possibly be the target for the
development of novel anticancer agents. Lin et al. [7]
demonstrated suppression of lung tumor angiogenesis and
metastasis by andrographolide isolated from Andrographis
paniculata which downregulates HIF-1α. In addition,
inhibition of HIF-1α pathway by HIF-1α–siRNA displayed
a direct correlation with A549 cellular proliferation
and angiogenesis, a prerequisite for metastasis [26]. In
agreement to these studies, our results obtained also
showed the reduction of HIF-1α expression in A549
cells treated with Phyllanthus extracts. This in turn
led to the suppression of various target genes con-
trolled by HIF-1α via hypoxia-responsive-element
(HRE) [26], including angiogenesis, metabolism, cell
growth, and death [2].
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http://www.biomedcentral.com/1472-6882/13/271VEGF is another crucial angiogenic growth factor which
induces endothelial cell proliferation from the pre-existing
capillary bed for wound healing, tumor growth, and
metastasis. Its expression is therefore increased prior
to an invasive and metastatic phenotype [56]. Also iNOS,
one of the three distinct isoforms of NOS which is widely
expressed and often upregulated in multiple tumor
tissues [57] is expressed in tumor cells associated
with vascularization and hence, is probably another
important regulator of angiogenesis [56,57]. Nitric
oxide (NO) produced by NOS have been shown to
affect vascular permeability, induce extracellular matrix
degradation, trigger VEGF production, as well as stimulate
endothelial cell proliferation and migration [30]. Hence,
inhibition of VEGF and iNOS by Phyllanthus can greatly
reduce A549 angiogenesis, resulting in tumor cells
malnutrition and hypoxia thereby preventing tumor
growth, survival, and metastasis. Adenosine 5′-triphosphate,
a major source of energy for cells and its involvement in a
variety of cellular activities which are ATP-dependent is
often increased in tumor cells [58]. Downregulation of these
enzymes activities by Phyllanthus causes cellular energy
deficit that can result in cancer cell death. One example is
enolase which catalyzes conversion of 2-phosphoglyceric
acid (PGA) to phosphoenolpyruvate (PEP) in the
anabolic pathway during gluconeogenesis to enhance
aerobic glycolysis in cancer cells [59]. Other enzymes
suppressed include glyceraldehyde 3 phosphate dehydro-
genase, fructose-biphosphate aldolase A, phosphoglycerate
mutase 1, and triosephosphate isomerase that are also in-
volved in energy metabolism [55,60].
Besides exploiting cellular signaling pathways for their
growth and metastasis, tumor cells possess efficient drug
detoxification system to remove compounds that may be
fatal to them. This includes upregulation of glutathione
transferase omega-1 that catalyzes binding of glutathione to
various anticancer compounds such as cisplatin, thereby
decreasing production of platinum-DNA adducts and ren-
dering them useless while glutathione synthetase catalyzes
production of glutathione substrate for the detoxifying
activity [61,62]. Similarly, metallothionein also plays a role
in chemotherapy binding and detoxification since its ele-
vated expression was noticed in several cisplatin-resistant
lung cancer cell lines [61]. Meanwhile, Annexin A4 is nor-
mally associated with chemoresistance in part by enhancing
drug efflux [63]. Inhibition of these detoxification enzymes
expressions in A549 after treatment with Phyllanthus as
demonstrated from the proteomic analysis therefore advo-
cates the reduced A549 drug-resistance capability resulting
in their susceptibility to death-inducing compounds.
Conclusions
All the findings obtained in this study point to the involve-
ment of ERK1/2 and hypoxia pathways which weresuppressed by Phyllanthus to inhibit A549 proliferation,
angiogenesis, invasion, and metastasis. Inhibition of
ERK1/2 pathway led to downregulation of invasion
and mobility proteins (MMP2; MMP7; MMP9; cytoskeletal
proteins), transcriptional proteins (proliferating cell nuclear
antigen; zinc finger protein), and antiapoptotic protein
(Bcl2) while inhibition of hypoxia pathway causes
repression of angiogenic proteins (VEGF; iNOS) and
various glycolytic enzymes. Suppression of drug detoxi-
fication enzymes such as gluthathione transferase and
metallothionein also increases sensitivity of A549 to
Phyllanthus treatment. Among the four Phyllanthus
species tested in this study, P. urinaria was found to be
the most effective to inhibit A549 growth and metastasis,
closely followed by P. watsonii. Thus, Phyllanthus could
be a valuable candidate in the treatment of metastatic can-
cers. However, the main concern before application of
Phyllanthus as an antimetastatic or antiproliferative agent
is its in vivo effect. Thus, further testing of the extracts ac-
tivity in vivo is necessary to exploit it as a chemotherapeu-
tic agent. Preliminary work has identified low toxicity of
Phyllanthus in an animal model as dosage greater than
50 g/kg is needed to cause 100% acute death in the mice
tested (unpublished data) and subsequent efficacy testing
in a tumor-bearing mice model needs to be carried out.
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